Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
April 09, 2025 | 11:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia is facing a class action lawsuit alleging securities fraud related to its NTLA-3001 program, which was discontinued as part of a major workforce reduction and strategic refocus.
The lawsuit and sudden program discontinuation suggest significant operational and strategic challenges for Intellia, likely to negatively impact investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100